---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000201"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:56:02.478139+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Recursion shareholders approve stock issuance for Exscientia acquisition

## Summary
- Shareholders voted 99.77% in favor (250.9M votes for) of issuing Class A common stock for the Exscientia acquisition.
- Proposal 2 (adjournment) deemed unnecessary after approval; not presented at Special Meeting.
- Special Meeting held Nov 12, 2024; quorum achieved with 253.5M votes present (72.5% of total eligible).

## SEC filing metadata
- accession: 0001601830-24-000201
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000201/0001601830-24-000201-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000201/rxrx-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000201
- JSON: https://secwatch.observer/filing/0001601830-24-000201.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000201.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.